• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去乙酰化酶抑制剂抗癌作用的分子基础。

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

作者信息

Epping Mirjam T, Bernards René

机构信息

Center for Biomedical Genetics and Cancer Genomics Centre, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

出版信息

Int J Biochem Cell Biol. 2009 Jan;41(1):16-20. doi: 10.1016/j.biocel.2008.07.020. Epub 2008 Aug 12.

DOI:10.1016/j.biocel.2008.07.020
PMID:18765293
Abstract

Histone deacetylase inhibitors comprise a variety of natural and synthetic compounds, which have in common that they inhibit enzymes that mediate the removal of acetyl groups from a range of proteins, including nucleosomal histones. Histone deacetylase inhibitors have anti-cancer activities in vitro and in vivo and are used in the clinic for the treatment of advanced cutaneous T cell lymphoma. The molecular pathways targeted by these compounds are discussed with an emphasis on the effects of these compounds on retinoic acid signaling.

摘要

组蛋白脱乙酰酶抑制剂包括多种天然和合成化合物,它们的共同之处在于能够抑制介导从一系列蛋白质(包括核小体组蛋白)中去除乙酰基的酶。组蛋白脱乙酰酶抑制剂在体外和体内均具有抗癌活性,并且在临床上用于治疗晚期皮肤T细胞淋巴瘤。本文将讨论这些化合物所靶向的分子途径,重点是这些化合物对视黄酸信号传导的影响。

相似文献

1
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂抗癌作用的分子基础。
Int J Biochem Cell Biol. 2009 Jan;41(1):16-20. doi: 10.1016/j.biocel.2008.07.020. Epub 2008 Aug 12.
2
HDAC inhibitors for the treatment of cancer.用于治疗癌症的组蛋白去乙酰化酶抑制剂
Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7.
3
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.表观遗传药物作为癌症治疗中的多效性药物:生物分子方面及临床应用
J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066.
4
Histone deacetylase inhibitors: overview and perspectives.组蛋白去乙酰化酶抑制剂:综述与展望。
Mol Cancer Res. 2007 Oct;5(10):981-9. doi: 10.1158/1541-7786.MCR-07-0324.
5
Development of histone deacetylase inhibitors for cancer treatment.用于癌症治疗的组蛋白去乙酰化酶抑制剂的研发。
Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583.
6
Histone deacetylase inhibitors in cancer therapy.组蛋白去乙酰化酶抑制剂在癌症治疗中的应用
Cancer Invest. 2006 Aug-Sep;24(5):521-7. doi: 10.1080/07357900600814979.
7
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.用于抗癌的表观遗传药物:从化学到癌症治疗,前路漫漫。
Int J Biochem Cell Biol. 2009 Jan;41(1):199-213. doi: 10.1016/j.biocel.2008.08.020. Epub 2008 Aug 22.
8
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.表观遗传学中的组蛋白去乙酰化:抗癌治疗的一个有吸引力的靶点。
Med Res Rev. 2005 May;25(3):261-309. doi: 10.1002/med.20024.
9
Histone deacetylase inhibitors as anti-neoplastic agents.组蛋白去乙酰化酶抑制剂作为抗肿瘤药物。
Cancer Lett. 2009 Aug 8;280(2):192-200. doi: 10.1016/j.canlet.2009.03.013. Epub 2009 Apr 3.
10
Histone deacetylase inhibitors: biology and mechanism of action.组蛋白去乙酰化酶抑制剂:生物学特性及作用机制
Cancer J. 2007 Jan-Feb;13(1):23-9. doi: 10.1097/PPO.0b013e31803c72ba.

引用本文的文献

1
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.组蛋白去乙酰化酶抑制作用的药物发现:锌结合基团的过去、现在与未来
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
2
Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.西达本胺通过促进Mcl-1降解抑制有氧代谢以诱导胰腺癌细胞生长停滞。
PLoS One. 2016 Nov 22;11(11):e0166896. doi: 10.1371/journal.pone.0166896. eCollection 2016.
3
Molecular basis of differentiation therapy for soft tissue sarcomas.
软组织肉瘤分化治疗的分子基础
Trends Cancer Res. 2010;6:69-90.
4
HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.组蛋白去乙酰化酶抑制诱导 MCF7 乳腺癌细胞中胆碱摄取增加和磷酸胆碱水平升高。
PLoS One. 2013 Apr 23;8(4):e62610. doi: 10.1371/journal.pone.0062610. Print 2013.
5
HDAC inhibitors in kidney development and disease.组蛋白去乙酰化酶抑制剂在肾脏发育和疾病中的作用。
Pediatr Nephrol. 2013 Oct;28(10):1909-21. doi: 10.1007/s00467-012-2320-8. Epub 2012 Oct 7.
6
γ-H2AX and other histone post-translational modifications in the clinic.γ-H2AX及其他组蛋白翻译后修饰在临床上的应用
Biochim Biophys Acta. 2012 Jul;1819(7):743-56. doi: 10.1016/j.bbagrm.2012.02.021. Epub 2012 Mar 9.
7
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.新型组蛋白去乙酰化酶抑制剂 AR42 在人类 T 淋巴细胞病毒 1 成人 T 细胞淋巴瘤小鼠模型中的疗效。
Leuk Res. 2011 Nov;35(11):1491-7. doi: 10.1016/j.leukres.2011.07.015. Epub 2011 Jul 29.
8
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.组蛋白去乙酰化酶抑制剂介导的癌细胞毒性:作用机制及潜在临床意义
Clin Cancer Res. 2009 Jun 15;15(12):3947-57. doi: 10.1158/1078-0432.CCR-08-2787. Epub 2009 Jun 9.